

Sjoukje J.C. van der Stegen<sup>1,2</sup>, Roseanna M. Petrovic<sup>1,2</sup>, Pieter L. Lindenbergh<sup>1,2</sup>, Wara Alexeeva<sup>1,2</sup>, Raedun Clarke<sup>3</sup>, Bahram Valamehr<sup>3</sup>, Isabelle Riviere<sup>4</sup>, Michel Sadelain<sup>1,2</sup>


1. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2. Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA, 3. Fate Therapeutics Inc, San Diego, CA, USA, 4. Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA

#### INTRODUCTION


T cell-derived iPSCs (TiPS) can provide a self-renewing source for in vitro CAR T cell production, resulting in a homogenous CAR+TCR+ TiPS-derived T (iT) cell population. However, in vitro differentiation yields iT cells with suboptimal features, generating cells that divert towards a CD8lphalpha innate-like phenotype. Premature expression of the T cell receptor (TCR) causes this diversion towards an innate-like phenotype. This can be partially averted by disabling the TCR but does not allow for maturation of the cells to a CD8 $\alpha\beta$  single-positive stage. In the absence of a TCR, careful control of CAR expression timing and calibrated signaling strength can uniquely drive adaptive iT cell differentiation to the CD4<sup>+</sup>CD8 $\alpha$ β<sup>+</sup> DP stage. CAR engagement at the DP stage subsequently facilitates maturation to CD8 $\alpha\beta$ single positive T cells, substituting for the TCR. DP cells upregulate 4-1BB expression upon CAR engagement and providing 4-1BBL costimulation enhances iT cell proliferation, persistence and in vivo function.

# 

### **METHODS**



CD5



# CONCLUSION

Regulated CAR expression can substitute for the TCR to drive DP T cell differentiation and CD8  $\alpha\beta$  SP T cell maturation. This remarkable finding suggests that the strength and timing of CAR signaling, together with the strength of Notch stimulation, are the essential drivers of  $\alpha\beta$  vs  $\gamma\delta$  lineage commitment.

4-1BB costimulation provided during maturation to the CD8 $\alpha\beta$  SP stage increases iT cell in vitro proliferation, in vivo persistence and in vivo cytotoxic function.

Enhanced 4-1BB costimulation through expression of 4-1BBL in iT cells further increases iT cell proliferation upon antigen exposure and in vivo persistence, thereby increasing in vivo tumor control and survival.

Collectively, TCR<sup>-</sup>CAR<sup>+</sup>41BBL<sup>+</sup>-iT cells have improved in vivo cytolytic function, without exposing to the risk of inducing graft-versus-host disease owing to the complete TCR<sup>-</sup> phenotype, and can be manufactured at scale and made available off-the-shelf for broad patient access

# 4-1BBL-iT CELLS HAVE IMPROVED IN VIVO PERSISTENCE AND CYTOLYTIC FUNCTION

